Literature DB >> 18611119

New emerging applications of molgramostim in acute myeloid leukaemia.

Xavier Thomas1.   

Abstract

BACKGROUND: Human granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates the proliferation and differentiation of hematopoietic progenitor cells in the myeloid lineage, and plays a key role in host defence and the inflammatory process. The main schedules adopted for clinical applications of GM-CSF in acute myeloid leukaemia (AML) were post-chemotherapy, in order to shorten the duration of neutropenia, and as a mobilising agent to induce release of progenitor cells from bone marrow into circulation.
METHODS: Based on the variety of biologic effects being attributed to GM-CSF, additional clinical uses for GM-CSF have been under investigation. Concurrent administration to chemotherapy has been used to recruit blast cells into active cell cycle phases, and to increase their sensitivity to cell cycle-dependent cytotoxic drugs. RESULTS/
CONCLUSION: Exposure to GM-CSF also has recently been shown to enhance cellular immunity and indirectly stimulate anti-tumour immunity. On the other hand, GM-CSF can directly enhance immunogenicity of tumours.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18611119     DOI: 10.1517/17425255.4.6.795

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  1 in total

1.  Evaluation of effectiveness of granulocyte-macrophage colony-stimulating factor therapy to cancer patients after chemotherapy: a meta-analysis.

Authors:  Wen-Liang Yu; Zi-Chun Hua
Journal:  Oncotarget       Date:  2018-06-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.